Evidence mapPaperPMID 41569660Full record

ArticleJCI insight2026

Reduced osteogenic factors and early osteoblast senescence in SOD1(G93A) ALS mouse model.

Burak Özkan, Jan-Moritz Ramge, Diana Wiesner, Jelena Scekic-Zahirovic, Stefano Antonucci, Sandra Nungeß, Dorothea Gebauer, Anita Ignatius, Jochen H Weishaupt, Melanie Haffner-Luntzer and 1 more

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Burak ÖzkanDepartment of Neurology, Ulm University, Ulm, Germany.
Jan-Moritz RamgeInstitute of Orthopaedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany.
Diana WiesnerGerman Center for Neurodegenerative Diseases (DZNE)-Ulm, Ulm, Germany.
Jelena Scekic-ZahirovicGerman Center for Neurodegenerative Diseases (DZNE)-Ulm, Ulm, Germany.
Stefano AntonucciDepartment of Neurology, Ulm University, Ulm, Germany.
Sandra NungeßInstitute of Orthopaedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany.
Dorothea GebauerInstitute of Orthopaedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany.
Anita IgnatiusInstitute of Orthopaedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany.
Jochen H WeishauptDepartment of Neurology, Ulm University, Ulm, Germany.
Melanie Haffner-LuntzerInstitute of Orthopaedic Research and Biomechanics, Ulm University Medical Center, Ulm, Germany.
Francesco RoselliDepartment of Neurology, Ulm University, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive motor neuron disease. Emerging evidence suggests manifestations beyond the neuromuscular system. Bone alterations are part of the ALS clinical picture; it remains unclear whether they are secondary to muscle denervation or due to an autonomous process. We investigated skeletal involvement in the SOD1(G93A) mouse model at presymptomatic (P45) and symptomatic (P110) stages through biomechanical and transcriptomic approaches. Three-point bending revealed significant reductions in femoral rigidity and maximum bending force in SOD1 mutants at P45, indicating early structural deficits. Micro-CT analysis demonstrated reduced trabecular bone mineral density and thickness at P45, with progressive trabecular loss and cortical thinning by P110. Histological examination revealed marked osteoblast loss at P45, suggesting impaired bone formation as the primary early mechanism. Transcriptomics of bulk bone and cultured osteoblasts from P45 mice identified dysregulation of bone differentiation, including downregulation of osteoblast differentiation genes and upregulation of negative regulators of ossification and increased cell senescence signatures. Unfolded protein response was upregulated in SOD1 osteoblasts. Immunohistochemistry confirmed the senescence phenotype with increased p16Ink4a level in SOD1 osteoblasts. These findings suggest that bone deterioration precedes overt motor symptoms and is linked to osteoblast premature senescence.

Indexed as

Amyotrophic Lateral SclerosisCellular SenescenceOsteoblastsOsteogenesisSuperoxide Dismutase-1AnimalsCell DifferentiationDisease Models, AnimalFemaleHumansMaleMiceMice, TransgenicX-Ray MicrotomographySod1 protein, mouseSuperoxide Dismutase-1Bone biologyCell biologyCellular senescenceNeurodegenerationNeuroscienceOsteoclast/osteoblast biology

Identifiers

PMID41569660
PMCPMC13041680

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.